Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aspen

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

Novartis building

Novartis drawn into Chinese corruption probe

Former sales rep files bribery complaint about Sandostatin LAR prescribing practices

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

INC Research expands into Japan

CRO strengthens its APAC capabilities with Osaka and Tokyo offices

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

Novartis building

Novartis lifts 2013 guidance on delay to Diovan generics

Reveals scale of payments to former CEO Daniel Vasella

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

Novartis day

Lucentis cleared in Europe for pathological myopia

Makes Novartis' drug the first anti-VEGF approved in this setting

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links